56 results
SC 14D9/A
STSA
Satsuma Pharmaceuticals Inc
24 May 23
Tender offer solicitation (amended)
9:40pm
and cash equivalents
Current assets
Noncurrent assets
Total assets
Current liabilities
Long-term debt, net
Noncurrent liabilities
Total liabilities
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
18 May 23
January 2024 PDUFA date expected
4:20pm
in June 2021 and the STS101 ASCEND Phase 3 long-term, open-label safety trial in which 446 subjects treated more than 9,000 migraine attacks with more
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
of EMERGE trial results and other data, including preliminary results from the open-label, Phase 3 long-term safety trial of STS101 5.2 mg, or ASCEND … ) the ongoing Phase 3 SUMMIT trial and results to date of the ongoing ASCEND open-label, long-term safety trial, (iv) and engaging a financial advisor
10-K/A
2022 FY
STSA
Satsuma Pharmaceuticals Inc
28 Apr 23
Annual report (amended)
4:08pm
. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business … the achievement of shorter-term goals, our long-term equity awards represent a longer-term compensation structure that promotes retention and continuous
SC14D9C
sh75wg qba9r5ntw
17 Apr 23
Written communication relating to third party tender offer
4:02pm
8-K
EX-2.1
p71acq
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
2w1m dgol
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-99.1
woezb
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-99.2
arup7m uqiqt
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
zq55nd
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
0i98nwisiflua5mgsp10
30 Nov 22
Other Events
4:00pm
8-K
EX-99.1
so33pjr6z3bhu ncj5x9
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
8-K
EX-99.2
lct10jl
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
8-K
EX-1.1
4dmy zsonrmrh
3 Nov 22
Entry into a Material Definitive Agreement
4:45pm
424B5
7yfle2s8wfgl04p6 yi
3 Nov 22
Prospectus supplement for primary offering
4:42pm
8-K
EX-99.1
ntqrugek6omk2kn
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
v0b2bgl5
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm
8-K
EX-99.1
1i3 d19xk
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm